Abstract
Sibutramine-induced weight loss and weight maintenance lead to clinically relevant reductions in risk factors associated with the metabolic syndrome. Treatment with the drug decreases visceral fat, improves lipid levels, decreases glycosylated haemoglobin and decreases uric acid concentrations. Sibutramine is effective in achieving weight loss in patients with type 2 diabetes but weight loss occurs more slowly than in non-diabetic patients. The criteria for predicting response to treatment in uncomplicated patients may not be appropriate to those with type 2 diabetes. Furthermore, it is important to set realistic goals for weight loss in type 2 diabetes to avoid the risk of denying effective treatment to patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Krejs, G. Metabolic benefits associated with sibutramine therapy. Int J Obes 26 (Suppl 4), S34–S37 (2002). https://doi.org/10.1038/sj.ijo.0802217
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijo.0802217
Keywords
This article is cited by
-
Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome
Current Hypertension Reports (2016)
-
Correlation between weight loss and improvement of diabetes mellitus among obese type 2 diabetic patients
Diabetology International (2013)
-
Remission of metabolic syndrome following a 15-week low-calorie lifestyle change program for weight loss
International Journal of Obesity (2009)
-
Impact of treating the metabolic syndrome on chronic kidney disease
Nature Reviews Nephrology (2009)
-
Influence of weight reduction by sibutramine on female sexual function
International Journal of Obesity (2006)